Sanofi/Genzyme: Emblematic of What Big Pharma's Buying Now
Sanofi-Aventis' much publicized pursuit - first hostile, then friendly - of Genzyme dominated biopharma news flow for more than half a year, with well timed information leaks and dramatic "he said, he said" commentary from the firms' CEOs. Such back and forth ensured continued high profile coverage until the companies officially affianced. But beyond the drama, the $20.1 billion deal, among the largest since the 2009 mega-mergers between Pfizer and Wyeth and Merck & Co. and Schering-Plough Corp., is worth discussion because it provides insight into what now drives big pharma dealmaking in the post-blockbuster era - and how companies want to pay for it.
Read the full article – start your free trial today!
Join thousands of industry professionals who rely on In Vivo for daily insights
Kura Oncology's new chief medical officer discusses her path to leadership, the company's advancing AML pipeline, and her methodical approach to developing treatments for underserved oncology indications.
Metsera CEO Whit Bernard applies an unconventional leadership philosophy to develop next-generation obesity therapeutics, including monthly GLP-1 injections and oral peptides.
From chemical engineering to cancer innovation, AbbVie's rising oncology leader is advancing next-generation ADCs to tackle difficult-to-treat tumors with a patient-centered approach.
Annual survey of patients and professionals shows how attitudes to health system transformation are evolving and what stakeholders are demanding as acceptance of AI tools accelerates.
BioWales in London 2025 showcased the efforts healthtech innovators are making to meet investors on their own turf, illustrating changing attitudes and evolving needs.
Metsera CEO Whit Bernard applies an unconventional leadership philosophy to develop next-generation obesity therapeutics, including monthly GLP-1 injections and oral peptides.